Active Biotech's rights issue completed
December 12 2016 - 11:31AM
NOT FOR
RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, JAPAN OR CANADA OR IN ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD
BE UNLAWFUL.
Following
the end of the subscription period, the results of Active Biotech's
rights issue show that 6,643,426 shares, corresponding to
approximately 96 percent of the shares offered, were subscribed for
with subscription rights. The remaining 272,596 shares have been
subscribed for by the guarantor MGA Holding AB. Through the rights
issue, Active Biotech receives proceeds amounting to approximately
SEK 55 million, before issue expenses.
As a result of the rights issue
Active Biotech's share capital increases by approximately SEK
26,068,856.73 to approximately SEK 364,964,039.37 and the total
number of shares and votes increases by 6,916,022 to
96,824,320.
Trading in the new shares on
Nasdaq Stockholm is expected to commence on or about 27 December
2016.
For further information, please
contact:
Tomas Leanderson, CEO
Tel: +46 (0)46 19 20 95
E-mail: tomas.leanderson@activebiotech.com
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com
Active Biotech
AB
P.O. Box 724, SE-220 07 Lund, Sweden
Phone +46 (0)46 19 20 00
Active Biotech AB (publ) (NASDAQ
Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in pivotal Phase 3 development for the treatment of
relapsing remitting multiple sclerosis. Also, laquinimod is in
Phase 2 development for the treatment of primary progressive
multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, paquinimod
och SILC projects. Please visit www.activebiotech.com for more
information.
This information
is information that Active Biotech AB is obliged to make public
pursuant to the EU Market Abuse Regulation. This information was
submitted for publication, through the agency of the contact
persons set out above, at 17.31 a.m. CET on 12
December 2016.
Important information
This press release is not an offer to subscribe for shares in
Active Biotech and investors should not subscribe for or purchase
any securities, except on the basis of information provided in the
prospectus.
This
press release may not be made public, released or distributed,
directly or indirectly, in or into the United States, Australia,
Japan or Canada or in any other jurisdiction in which the
distribution of this press release would be unlawful. Further, this
press release does not constitute an offer to sell new shares,
interim shares ("BTA") or subscription rights to any person in any
jurisdiction in which it is unlawful to make such offer to such
person or where such action would require additional prospectuses,
registration or other measures other than those pursuant to Swedish
law. The prospectus, application form and other documents
associated with the rights issue may not be distributed in or to
any country where such distribution or the rights issue would
require such measures set forth in the preceding sentence or be in
violation of the regulations of such country.
The new
shares and subscription rights have not been recommended or
approved by any United States federal or state securities
commission or regulatory authority. No new shares, BTA,
subscription rights or other securities issued by Active Biotech
have been or will be registered under the U.S. Securities Act of
1933, as amended, or under the securities legislation in any state
of the United States, and may not be offered, exercised or sold in
the United States absent registration or an applicable exemption
from registration requirements. There is no intention to register
any portion of the rights issue in the United States or to conduct
a public offering of securities in the United States.
The
Company has not authorized any offer of the securities referred to
herein to the public in any country in the European Economic Area
("EEA") other than Sweden. In other member states in the EEA, the
securities may only be offered to (a) any legal entity which is a
qualified investor as defined in the Directive 2003/71/EC (the
"Prospectus Directive"); or (b) any person falling within Article
3(2) of the Prospectus Directive.
In the
United Kingdom, this communication is only being distributed to,
and is only directed at "qualified investors" (as defined in
section 86(7) of the Financial Services and Markets Act 2000) who
are (i) investment professionals falling within the meaning of
Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order"); or (ii) persons
falling within Article 49(2)(a) to (d) ("high net worth companies,
unincorporated associations, etc.") of the Order (all such persons
together being referred to as "relevant persons"). In the United
Kingdom, any investment or investment activity to which this
communication relates is available only to, and will be engaged in
only with, relevant persons. Any person who is not a relevant
person should not take any action on the basis of this
communication and should not act or rely on it or any of its
contents.
This
press release contains forward-looking statements which reflect
Active Biotech's current view on future events and financial and
operational development. Words such as "intend", "will", "expect",
"anticipate", "may", "plan", "estimate" and other expressions that
imply indications or predictions of future development or trends,
constitute forward-looking statements. Forward-looking statements
inherently involve both known and unknown risks and uncertainties
as they depend on future events and circumstances. Forward-looking
statements do not guarantee future results or development and the
actual outcome could differ materially from the forward-looking
statements. The information, opinions and forward-looking
statements included in this press release speak only as of its date
and are subject to change without notice.
Active Biotech’s rights issue
completed
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Sep 2023 to Sep 2024